Campbell Bunce leads Abzena’s scientific operations, bringing over 19 years’ experience working in the biotech and diagnostics sectors, occupying senior management positions with Piramed Pharma, Immune Targeting Systems and Oxford Immunotec. Campbell has a Ph.D. in immunology from the University of Manchester and has published a number of papers in T cell biology, immunomodulators and vaccines.